BTIG Stick to Their Buy Rating for Stryker Corporation By Investing.com – Investing.com

BTIG analyst Ryan Zimmerman maintained a Buy rating on Stryker Corporation (NYSE:) on Thursday, setting a price target of $284, which is approximately 5.77% above the present share price of $268.5.

Zimmerman expects Stryker Corporation to post earnings per share (EPS) of $1.57 for the fourth quarter of 2021.

The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Stryker, with an average price target of $301.75.The analysts price targets range from a high of $320 to a low of $284.

In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $4.29 billion and a net profit of $808 million. The company's market cap is $101.25 billion.

According to TipRanks.com, BTIG analyst Ryan Zimmerman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 23.9% and a 56.41% success rate.

Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Read the original here:

BTIG Stick to Their Buy Rating for Stryker Corporation By Investing.com - Investing.com